Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Dana-Farber Cancer Institute · University of Louisville · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
979
total citations
- FWCI
- 69.80
- Percentile
- 100%
- References
- 22
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Ipilimumab
- Medicine
- Nivolumab
- Internal medicine
- Clinical endpoint
- Melanoma
- Placebo
- Clinical trial
No related works found for this paper.